Paul Dillon

4.3k total citations · 1 hit paper
71 papers, 3.3k citations indexed

About

Paul Dillon is a scholar working on Epidemiology, Toxicology and Pharmacology. According to data from OpenAlex, Paul Dillon has authored 71 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 13 papers in Toxicology and 11 papers in Pharmacology. Recurrent topics in Paul Dillon's work include Forensic Toxicology and Drug Analysis (13 papers), Substance Abuse Treatment and Outcomes (12 papers) and Psychedelics and Drug Studies (8 papers). Paul Dillon is often cited by papers focused on Forensic Toxicology and Drug Analysis (13 papers), Substance Abuse Treatment and Outcomes (12 papers) and Psychedelics and Drug Studies (8 papers). Paul Dillon collaborates with scholars based in Australia, Ireland and United States. Paul Dillon's co-authors include Jan Copeland, Peter Gates, Louisa Degenhardt, Mark A Bellis, Karen Hughes, Wendy Swift, Д. А. Шапиро, Julie Hando, Mark Kipnes and Paul Clopton and has published in prestigious journals such as Gastroenterology, Hepatology and Clinical Cancer Research.

In The Last Decade

Paul Dillon

68 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

2013 767 citations Sunder Mudaliar, Robert R. Henry et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Dillon Australia	23	1.2k	786	673	562	418	71	3.3k
Paul Glue New Zealand	46	1.1k 0.9×	1.5k 1.9×	124 0.2×	647 1.2×	169 0.4×	230	6.5k
Lucy Burns Australia	41	2.3k 1.9×	454 0.6×	492 0.7×	970 1.7×	132 0.3×	189	5.9k
Paul Haber Australia	48	4.0k 3.3×	769 1.0×	201 0.3×	583 1.0×	516 1.2×	296	9.4k
Marie Claire Van Hout United Kingdom	31	1.1k 0.9×	334 0.4×	505 0.8×	706 1.3×	314 0.8×	257	3.6k
Steven Duffy United Kingdom	24	549 0.5×	1.4k 1.7×	159 0.2×	341 0.6×	156 0.4×	68	3.6k
Amy Peacock Australia	32	3.2k 2.7×	1.1k 1.4×	764 1.1×	890 1.6×	89 0.2×	200	5.9k
Theresa HM Moore United Kingdom	26	658 0.6×	1.5k 1.9×	74 0.1×	822 1.5×	377 0.9×	79	5.9k
Andriy V. Samokhvalov Canada	22	2.5k 2.1×	247 0.3×	60 0.1×	316 0.6×	350 0.8×	45	4.2k
Antoni Gual Spain	41	4.1k 3.4×	713 0.9×	80 0.1×	839 1.5×	482 1.2×	268	7.1k
Wei Hao China	37	1.2k 1.0×	534 0.7×	123 0.2×	744 1.3×	130 0.3×	205	4.9k

Countries citing papers authored by Paul Dillon

Since Specialization

Citations

This map shows the geographic impact of Paul Dillon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Dillon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Dillon more than expected).

Fields of papers citing papers by Paul Dillon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Dillon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Dillon. The network helps show where Paul Dillon may publish in the future.

Co-authorship network of co-authors of Paul Dillon

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Dillon. A scholar is included among the top collaborators of Paul Dillon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Dillon. Paul Dillon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dillon, Paul, et al.. (2023). Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis. Multiple Sclerosis and Related Disorders. 71. 104512–104512. 2 indexed citations

MacLean, Sarah, Megan Cook, Paul Dillon, & Cassandra Wright. (2023). Educating students about volatile substance use in Australian schools: Is the current approach evidence‐based, and how should we do it?. Health Promotion Journal of Australia. 35(4). 1393–1396.

Zhu, Andrew X., Farshid Dayyani, Chia‐Jui Yen, et al.. (2022). Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical Cancer Research. 28(16). 3537–3545. 75 indexed citations

Hughes, Richard A., Hans‐Martin Schneble, Erwan Muros‐Le Rouzic, et al.. (2020). COVID-19 in ocrelizumab-treated people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 49. 102725–102725. 54 indexed citations

Dillon, Paul, et al.. (2020). A real-world data study of coronavirus-2019 disease severity in patients with multiple sclerosis treated with ocrelizumab. Multiple Sclerosis Journal. 26. 103–104. 2 indexed citations

Dillon, Paul, Susan M. Smith, Paul Gallagher, & Gráinne Cousins. (2019). Association between gaps in antihypertensive medication adherence and injurious falls in older community-dwelling adults: a prospective cohort study. BMJ Open. 9(3). e022927–e022927. 12 indexed citations

Dillon, Paul, Ronald McDowell, Susan M. Smith, Paul Gallagher, & Gráinne Cousins. (2019). Determinants of intentions to monitor antihypertensive medication adherence in Irish community pharmacy: a factorial survey. BMC Family Practice. 20(1). 131–131. 5 indexed citations

Mudaliar, Sunder, Robert R. Henry, Arun J. Sanyal, et al.. (2013). Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 145(3). 574–582.e1. 767 indexed citations breakdown →

O’Sullivan, Mary P., Paul Dillon, Paul Gallagher, et al.. (2011). Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb). Journal of Materials Science Materials in Medicine. 23(1). 89–98. 20 indexed citations

10.

Hall, Kate, et al.. (2011). MAKINGtheLINK: a school-based health promotion programme to increase help-seeking for cannabis and mental health issues among adolescents. Early Intervention in Psychiatry. 5(1). 81–88. 16 indexed citations

11.

Pumarola, Tomàs, et al.. (2010). Performance evaluation of the ADVIA Centaur® HIV Ag/Ab Combo assay. Journal of Virological Methods. 170(1-2). 16–20. 18 indexed citations

12.

Lancaster, Kari, et al.. (2010). Illicit drugs and the media: Models of media effects for use in drug policy research. Drug and Alcohol Review. 30(4). 397–402. 84 indexed citations

13.

Mudaliar, Sunder, Linda Morrow, Paul Dillon, et al.. (2009). A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY. Hepatology. 50(4). 18 indexed citations

14.

Larance, Briony, Louisa Degenhardt, Jan Copeland, & Paul Dillon. (2008). Injecting risk behaviour and related harm among men who use performance‐ and image‐enhancing drugs. Drug and Alcohol Review. 27(6). 679–686. 67 indexed citations

15.

Shearer, James, Jennifer Johnston, Craig Fry, et al.. (2007). Contemporary cocaine use patterns and associated harms in Melbourne and Sydney, Australia. Drug and Alcohol Review. 26(5). 537–543. 21 indexed citations

16.

Copeland, Jan, Richard J. Stevenson, Peter Gates, & Paul Dillon. (2007). Young Australians and alcohol: the acceptabllity of ready‐to‐drink (RTD) alcoholic beverages among 12–30‐year‐olds. Addiction. 102(11). 1740–1746. 30 indexed citations

17.

Swift, Wendy, Peter Gates, & Paul Dillon. (2005). Survey of Australians using cannabis for medical purposes. Harm Reduction Journal. 2(1). 18–18. 95 indexed citations

18.

Degenhardt, Louisa, Shane Darke, & Paul Dillon. (2003). The prevalence and correlates of gamma‐hydroxybutyrate (GHB) overdose among Australian users. Addiction. 98(2). 199–204. 69 indexed citations

19.

Degenhardt, Louisa, Shane Darke, & Paul Dillon. (2002). GHB use among Australians: characteristics, use patterns and associated harm. Drug and Alcohol Dependence. 67(1). 89–94. 112 indexed citations

20.

Dillon, Paul. (1983). Sobre la antropología totalizadora. Anthropologica. 1(1). 159–207.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact